JAX Mouse Strain Datasheet - 006849

B6.129P2-Mecp2^tm2Bird/J

Stock No:: 006849 |; Mecp2^lox-stop

Repository Live

Overview

Also Known As: Mecp2^lox-stop

Mice with this X-linked lox-STOP mutation of the methyl CpG binding protein 2 gene may be useful in neurological and developmental studies of Rett syndrome and its amelioration upon excision of the lox-STOP cassette.

Donating Investigator

Adrian Bird, University of Edinburgh

Genetic overview

Genetic Background	Generation
	N6+N25 (13-APR-16)

Mecp2^tm2Bird

Allele Type	Gene Symbol	Gene Name
Targeted (Conditional ready (e.g. floxed), Null/Knockout)	Mecp2	methyl CpG binding protein 2

View Genetics

Research Applications

Neurobiology Research
Research Tools

View All Research Applications

Base Price

Starting at:

$224.00 Domestic price for female

$298.00 Domestic price for breeder pair

View Price List

Details

Detailed Description

These mice possess a loxP-flanked STOP cassette in intron 2 of the targeted gene on the X chromosome. Western blot and hybridization analysis confirm the absence of wildtype protein from the targeted allele (although the donating investigator reports that the targeted allele produces a "read-through" transcript which does not give rise to detectable levels of protein but makes it difficult to discriminate between the "flox-stopped" and reactivated alleles by RT-PCR). Hemizygous (Mecp2^lox-Stop/y) males do not breed and develop Rett syndrome symptoms (reduced mobility, hindlimb clasping) at approximately 6 weeks of age, with death occurring at approximately 11 weeks of age. Heterozygous females are fertile until developing Rett syndrome characteristics at 4-12 months of age. This Rett syndrome-like phenotype is similar to that observed for the traditional knock-out allele (see Stock No. 003890). Cre recombinase-mediated removal of the floxed-STOP cassette restores transcription from the targeted allele and MECP2 protein activity to normal, and reverses the Rett syndrome-like neurological defects.

This mutant mouse strain may be bred to a strain expressing tamoxifen inducible Cre recombinase in most tissues (see Stock No. 004682).

Mice with this X-linked lox-STOP mutation may be useful in neurological and developmental studies of Rett syndrome and its amelioration upon excision of the lox-STOP cassette.

Development

A targeting vector was designed to insert a loxP-flanked STOP-Neo cassette into intron 2 of the targeted gene. The STOP-Neo cassette is composed of a PGK-Neo cassette followed by the 3' portion of the yeast His3 gene, an SV40 polyadenylation sequence, and a false translation initiation codon followed by a 5' splice donor site. The construct was electroporated into 129P2/OlaHsd-derived E14TG2a embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts, and chimeric offspring were bred to C57BL/6 mice. Heterozygous female mutants were bred to wild-type C57BL/6 males for 5 generations prior to arrival at The Jackson Laboratory. A SNP (single nucleotide polymorphism) panel analysis performed in April 2009 by The Jackson Laboratory revealed that this strain was on a mixed B6;129 genetic background background. Further backcrossing to C57BL/6J inbred mice generated mutant mice congenic on a C57BL/6 genetic background (confirmed by SNP analysis August 2009).

Control Suggestions

Wild-type from the colony
000664 C57BL/6J

Additional Information

Considerations for Choosing Controls

Selected References

Guy J; Gan J; Selfridge J; Cobb S; Bird A. 2007. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315(5815):1143-7. PubMed: 17289941 MGI: J:118365

View All References

Genetics

Mecp2^tm2Bird

Allele Symbol: Mecp2^tm2Bird

Allele Name	targeted mutation 2, Adrian Bird
Allele Type	Targeted (Conditional ready (e.g. floxed), Null/Knockout)
Allele Synonym(s)	Mecp2^lox-stop; Mecp2^stop
Gene Symbol and Name	Mecp2, methyl CpG binding protein 2
Gene Synonym(s)	1500041B07Rik; 1500041B07Rik; AUTSX3; BB130002; D630021H01Rik; D630021H01Rik; MRX16; MRX79; MRXS13; MRXSL; Mbd5; PPMX; RIKEN cDNA 1500041B07 gene; RIKEN cDNA D630021H01 gene; RS; RTS; RTT; WBP10; expressed sequence BB130002
Strain of Origin	129P2/OlaHsd
Chromosome	X
Molecular Note	Cre recombinase-reversible gene inactivation was accomplished by insertion into intron 2 of a 3.1-kb DNA fragment containing a loxP-flanked "neostop" cassette, which comprises a neomycin resistance cassette followed by a transcriptional/translational "stop" cassette composed of 550 bp of 3' sequence from the Saccharomyces cerevisiae His3 gene, an SV40 polyadenylation sequence, and a synthetic sequence containing a false translation initiation codon (ATG) immediately followed by a consensus splice donor sequence. Despite the production of a read-through transcript, no protein product was detected by western blot or immunofluorescence analysis of brains of mutant mice.
Mutations Made By	Adrian Bird, University of Edinburgh

Disease/Phenotype

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Neurobiology Research
- Behavioral and Learning Defects
- Cre-lox System
  - loxP-flanked Sequences
- Neurodevelopmental Defects
  - Rett's syndrome
Research Tools
- Cre-lox System
  - loxP-flanked Sequences
- Developmental Biology Research
  - Cre-lox System

Genotype: Mecp2^tm2Bird related

Neurobiology Research
- Ataxia (Movement) Defects

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Mecp2^tm2Bird/Mecp2⁺
involves: 129P2/OlaHsd * C57BL/6

behavior/neurological phenotype

abnormal behavior
- at 4 to 12 months of age, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)

limb grasping
- at 4 to 12 months of age

tremors
- at 4 to 12 months of age

growth/size/body region phenotype

obese
- mice exhibit excess weight gain

nervous system phenotype

reduced long term potentiation
- mice develop a reduction in long term potentiation

respiratory system phenotype

abnormal breathing pattern
- at 4 to 12 months of age

Genotype: Mecp2^tm2Bird/Y
involves: 129P2/OlaHsd * C57BL/6

mortality/aging

premature death
- male mice survive on average 11 weeks from birth

behavior/neurological phenotype

abnormal behavior
- at 12 weeks mice display low stance, inertia, tremor, arrhythmic breathing, splayed himdlimb and moderate hindlimb clasping
- during the last 4 weeks of life, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)

limb grasping
- at 12 weeks, mice display moderate hindlimb clasping

tremors
- at 12 weeks

respiratory system phenotype

abnormal breathing pattern
- at 12 weeks

The following phenotype relates to a compound genotype created using this strain

Genotype: Mecp2^tm2Bird/Mecp2⁺ Tg(CAG-cre/Esr1)5Amc/?
involves: 129P2/OlaHsd C57BL/6 * CBA

behavior/neurological phenotype

abnormal behavior
- at 4 to 12 months of age, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)
- however, tamoxifen treatment after the onset of symptoms reverses symptom progression

limb grasping
- at 4 to 12 months of age
- however, tamoxifen treatment after the onset of symptoms reverses symptom progression

tremors
- at 4 to 12 months of age
- however, tamoxifen treatment after the onset of symptoms reverses symptom progression

nervous system phenotype

reduced long term potentiation
- however, treatment with tamoxifen returns long term potentiation to normal levels
- mice develop a reduction in long term potentiation

respiratory system phenotype

abnormal breathing pattern
- at 4 to 12 months of age
- however, tamoxifen treatment after the onset of symptoms reverses symptom progression

growth/size/body region phenotype

obese
- however, tamoxifen treatment after the onset of symptoms reverses weight gain
- mice exhibit excess weight gain

Genotype: Mecp2^tm2Bird/Y Tg(CAG-cre/Esr1)5Amc/0
involves: 129P2/OlaHsd C57BL/6 * CBA

mortality/aging

premature death
- 9 of 17 mice treated with tamoxifen at 3 to 4 weeks of age die soon after treatment
- however, tamoxifen-tocixity is not responsible for observed deaths, 8 of 17 mice treated with tamoxifen at 3 to 4 weeks of age have a normal life span, and mice treated with tamoxifen from week 12 to 17 exhibit normal lethality

behavior/neurological phenotype

abnormal behavior
- at 12 weeks mice display low stance, inertia, tremor, arrhythmic breathing, splayed himdlimb and moderate hindlimb clasping
- during the last 4 weeks of life, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)
- mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms

behavior/neurological phenotype
- the surviving 8 of 17 mice treated with tamoxifen at 3 to 4 weeks of age exhibit normal behavior/neurological phenotypes

limb grasping
- at 12 weeks, mice display moderate hindlimb clasping
- mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms

tremors
- at 12 weeks
- mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms

respiratory system phenotype

abnormal breathing pattern
- at 12 weeks
- mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms

References

Guy J; Gan J; Selfridge J; Cobb S; Bird A. 2007. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315(5815):1143-7. PubMed: 17289941 MGI: J:118365

Additional References

Dragatsis I; Zeitlin S. 2001. A method for the generation of conditional gene repair mutations in mice. Nucleic Acids Res 29(3):E10. PubMed: 11160912 MGI: J:111323

Additional - Mecp2^tm2Bird related

Cortelazzo A; De Felice C; Guerranti R; Signorini C; Leoncini S; Pecorelli A; Scalabri F; Madonna M; Filosa S; Della Giovampaola C; Capone A; Durand T; Mirasole C; Zolla L; Valacchi G; Ciccoli L; Guy J; D'Esposito M; Hayek J. 2016. Abnormal N-glycosylation pattern for brain nucleotide pyrophosphatase-5 (NPP-5) in Mecp2-mutant murine models of Rett syndrome. Neurosci Res 105:28-34. PubMed: 26476268 MGI: J:231839
Cronk JC; Derecki NC; Ji E; Xu Y; Lampano AE; Smirnov I; Baker W; Norris GT; Marin I; Coddington N; Wolf Y; Turner SD; Aderem A; Klibanov AL; Harris TH; Jung S; Litvak V; Kipnis J. 2015. Methyl-CpG Binding Protein 2 Regulates Microglia and Macrophage Gene Expression in Response to Inflammatory Stimuli. Immunity 42(4):679-91. PubMed: 25902482 MGI: J:229774
De Felice C; Della Ragione F; Signorini C; Leoncini S; Pecorelli A; Ciccoli L; Scalabri F; Marracino F; Madonna M; Belmonte G; Ricceri L; De Filippis B; Laviola G; Valacchi G; Durand T; Galano JM; Oger C; Guy A; Bultel-Ponce V; Guy J; Filosa S; Hayek J; D'Esposito M. 2014. Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome. Neurobiol Dis 68:66-77. PubMed: 24769161 MGI: J:214008
Derecki NC; Cronk JC; Lu Z; Xu E; Abbott SB; Guyenet PG; Kipnis J. 2012. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484(7392):105-9. PubMed: 22425995 MGI: J:183878
Dragatsis I; Zeitlin S. 2001. A method for the generation of conditional gene repair mutations in mice. Nucleic Acids Res 29(3):E10. PubMed: 11160912 MGI: J:111323
Durand S; Patrizi A; Quast KB; Hachigian L; Pavlyuk R; Saxena A; Carninci P; Hensch TK; Fagiolini M. 2012. NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron 76(6):1078-90. PubMed: 23259945 MGI: J:197657
Gadalla KK; Ross PD; Riddell JS; Bailey ME; Cobb SR. 2014. Gait analysis in a Mecp2 knockout mouse model of Rett syndrome reveals early-onset and progressive motor deficits. PLoS One 9(11):e112889. PubMed: 25392929 MGI: J:225153
Goffin D; Brodkin ES; Blendy JA; Siegel SJ; Zhou Z. 2014. Cellular origins of auditory event-related potential deficits in Rett syndrome. Nat Neurosci 17(6):804-6. PubMed: 24777420 MGI: J:212933
Herrera JA; Ward CS; Wehrens XH; Neul JL. 2016. Methyl-CpG binding-protein 2 function in cholinergic neurons mediates cardiac arrhythmogenesis. Hum Mol Genet 25(22):4983-4995. PubMed: 28159985 MGI: J:241788
Huang TW; Kochukov MY; Ward CS; Merritt J; Thomas K; Nguyen T; Arenkiel BR; Neul JL. 2016. Progressive Changes in a Distributed Neural Circuit Underlie Breathing Abnormalities in Mice Lacking MeCP2. J Neurosci 36(20):5572-86. PubMed: 27194336 MGI: J:231950
Kamal B; Russell D; Payne A; Constante D; Tanner KE; Isaksson H; Mathavan N; Cobb SR. 2015. Biomechanical properties of bone in a mouse model of Rett syndrome. Bone 71:106-14. PubMed: 25445449 MGI: J:219301
Kernohan KD; Jiang Y; Tremblay DC; Bonvissuto AC; Eubanks JH; Mann MR; Berube NG. 2010. ATRX partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain. Dev Cell 18(2):191-202. PubMed: 20159591 MGI: J:158584
Lakso M; Sauer B; Mosinger B Jr; Lee EJ; Manning RW; Yu SH; Mulder KL; Westphal H. 1992. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci U S A 89(14):6232-6. PubMed: 1631115 MGI: J:75205
Lang M; Wither RG; Brotchie JM; Wu C; Zhang L; Eubanks JH. 2013. Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice. Hum Mol Genet 22(2):358-71. PubMed: 23077217 MGI: J:191128
Lang M; Wither RG; Colic S; Wu C; Monnier PP; Bardakjian BL; Zhang L; Eubanks JH. 2014. Rescue of behavioral and EEG deficits in male and female Mecp2-deficient mice by delayed Mecp2 gene reactivation. Hum Mol Genet 23(2):303-18. PubMed: 24009314 MGI: J:204519
Lioy DT; Garg SK; Monaghan CE; Raber J; Foust KD; Kaspar BK; Hirrlinger PG; Kirchhoff F; Bissonnette JM; Ballas N; Mandel G. 2011. A role for glia in the progression of Rett's syndrome. Nature 475(7357):497-500. PubMed: 21716289 MGI: J:174777
Lombardi LM; Baker SA; Zoghbi HY. 2015. MECP2 disorders: from the clinic to mice and back. J Clin Invest 125(8):2914-23. PubMed: 26237041 MGI: J:225796
McLeod F; Ganley R; Williams L; Selfridge J; Bird A; Cobb SR. 2013. Reduced seizure threshold and altered network oscillatory properties in a mouse model of Rett syndrome. Neuroscience 231:195-205. PubMed: 23238573 MGI: J:194298
Meng X; Wang W; Lu H; He LJ; Chen W; Chao ES; Fiorotto ML; Tang B; Herrera JA; Seymour ML; Neul JL; Pereira FA; Tang J; Xue M; Zoghbi HY. 2016. Manipulations of MeCP2 in glutamatergic neurons highlight their contributions to Rett and other neurological disorders. Elife 5:. PubMed: 27328325 MGI: J:234270
Nguyen MV; Felice CA; Du F; Covey MV; Robinson JK; Mandel G; Ballas N. 2013. Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology. J Neurosci 33(48):18764-74. PubMed: 24285883 MGI: J:204155
Orefice LL; Zimmerman AL; Chirila AM; Sleboda SJ; Head JP; Ginty DD. 2016. Peripheral Mechanosensory Neuron Dysfunction Underlies Tactile and Behavioral Deficits in Mouse Models of ASDs. Cell :. PubMed: 27293187 MGI: J:232023
Robinson L; Plano A; Cobb S; Riedel G. 2013. Long-term home cage activity scans reveal lowered exploratory behaviour in symptomatic female Rett mice. Behav Brain Res 250:148-56. PubMed: 23643691 MGI: J:198941
Ross PD; Guy J; Selfridge J; Kamal B; Bahey N; Tanner KE; Gillingwater TH; Jones RA; Loughrey CM; McCarroll CS; Bailey ME; Bird A; Cobb S. 2016. Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes. Hum Mol Genet :. PubMed: 27506980 MGI: J:238655
Schafer DP; Heller CT; Gunner G; Heller M; Gordon C; Hammond T; Wolf Y; Jung S; Stevens B. 2016. Microglia contribute to circuit defects in Mecp2 null mice independent of microglia-specific loss of Mecp2 expression. Elife 5:. PubMed: 27458802 MGI: J:235289
Su SH; Kao FC; Huang YB; Liao W. 2015. MeCP2 in the rostral striatum maintains local dopamine content critical for psychomotor control. J Neurosci 35(15):6209-20. PubMed: 25878291 MGI: J:221674
Ure K; Lu H; Wang W; Ito-Ishida A; Wu Z; He LJ; Sztainberg Y; Chen W; Tang J; Zoghbi HY. 2016. Restoration of Mecp2 expression in GABAergic neurons is sufficient to rescue multiple disease features in a mouse model of Rett syndrome. Elife 5:. PubMed: 27328321 MGI: J:234272
Ward CS; Arvide EM; Huang TW; Yoo J; Noebels JL; Neul JL. 2011. MeCP2 Is Critical within HoxB1-Derived Tissues of Mice for Normal Lifespan. J Neurosci 31(28):10359-70. PubMed: 21753013 MGI: J:174516
Weng SM; McLeod F; Bailey ME; Cobb SR. 2011. Synaptic plasticity deficits in an experimental model of rett syndrome: long-term potentiation saturation and its pharmacological reversal. Neuroscience 180:314-21. PubMed: 21296130 MGI: J:173701
Wither RG; Lang M; Zhang L; Eubanks JH. 2013. Regional MeCP2 expression levels in the female MeCP2-deficient mouse brain correlate with specific behavioral impairments. Exp Neurol 239:49-59. PubMed: 23022455 MGI: J:196997

Service	Genotype	Price
	X linked - Heterozygous Females and Wild-type Males for Mecp2<tm2Bird>

Terms Of Use

Terms of Use

General Terms and Conditions

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As: Mecp2lox-stop

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Mecp2tm2Bird

Allele Symbol: Mecp2tm2Bird

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Mecp2tm2Bird related

Mammalian Phenotype Terms by Genotype

Genotype: Mecp2tm2Bird/Mecp2+involves: 129P2/OlaHsd * C57BL/6

behavior/neurological phenotype

growth/size/body region phenotype

nervous system phenotype

respiratory system phenotype

Genotype: Mecp2tm2Bird/Yinvolves: 129P2/OlaHsd * C57BL/6

mortality/aging

behavior/neurological phenotype

respiratory system phenotype

Genotype: Mecp2tm2Bird/Mecp2+ Tg(CAG-cre/Esr1*)5Amc/?involves: 129P2/OlaHsd * C57BL/6 * CBA

behavior/neurological phenotype

nervous system phenotype

respiratory system phenotype

growth/size/body region phenotype

Genotype: Mecp2tm2Bird/Y Tg(CAG-cre/Esr1*)5Amc/0involves: 129P2/OlaHsd * C57BL/6 * CBA

mortality/aging

behavior/neurological phenotype

respiratory system phenotype

References

Additional References

Additional - Mecp2tm2Bird related

Genotyping Protocols

Dietary Information

Breeding Considerations

Mating System

Citation

Animal Health Reports

Live Mouse

Breeder Pair

Cryorecovery - Pricing

Progeny testing is not required

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms of Use

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Also Known As: Mecp2^lox-stop

Mecp2^tm2Bird

Allele Symbol: Mecp2^tm2Bird

Genotype: Mecp2^tm2Bird related

Genotype: Mecp2^tm2Bird/Mecp2⁺
involves: 129P2/OlaHsd * C57BL/6

Genotype: Mecp2^tm2Bird/Y
involves: 129P2/OlaHsd * C57BL/6

Genotype: Mecp2^tm2Bird/Mecp2⁺ Tg(CAG-cre/Esr1)5Amc/?
involves: 129P2/OlaHsd C57BL/6 * CBA

Genotype: Mecp2^tm2Bird/Y Tg(CAG-cre/Esr1)5Amc/0
involves: 129P2/OlaHsd C57BL/6 * CBA

Additional - Mecp2^tm2Bird related